REVIEW

Involvement of long non-coding RNAs in the progression of esophageal cancer

Wenhua Xue1,4,† | Yuanyuan Zheng1,3,† | Zhibo Shen1,2,3,† | Lifeng Li2,3 | Zhirui Fan2 | Wenbin Wang1 | Zijia Zhu1 | Yunkai Zhai3 | Jie Zhao1,3  | Quancheng Kan1,4

1 Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P. R. China
2 Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P. R. China
3 Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, Henan 450052, P. R. China
4 Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, Henan 450052, P. R. China

Abstract
Esophageal cancer (EC) is one of the most common malignant tumors of the digestive system with high incidence and mortality rate worldwide. Therefore, exploring the pathogenesis of EC and searching for new targeted therapies are the current research hotspot for EC treatment. Long non-coding RNAs (lncRNAs) are endogenous RNAs with more than 200 nucleotides, but without protein-coding function. In recent years, lncRNAs have gradually become the focuses in the field of non-coding RNA. Some lncRNAs have been proved to be closely related to the pathogenesis of EC. Many lncRNAs are abnormally expressed in EC and participate in many biological processes including cell proliferation, apoptosis, and metastasis by inhibiting or promoting target gene expression. LncRNAs can also regulate the progression of EC through epithelial-mesenchymal transformation (EMT), which is closely related to the occurrence, development, and...
prognosis of EC. In this article, we review and discuss the involvement of lncRNAs in the progression of EC.

**KEYWORDS**
apoptosis, biomarker, diagnosis, drug resistance, esophageal cancer, long non-coding RNA, metastasis, prognosis, proliferation

### 1 | INTRODUCTION

Esophageal cancer (EC) is one of the most common malignant tumors in the world and the fourth leading cause of all cancer deaths in China [1, 2]. In China, the main type of EC is esophageal squamous cell carcinoma (ESCC), accounting for about 90% of all cases of EC, and the remaining cases are esophageal adenocarcinoma [3]. In recent decades, EC has brought severe challenges to medical services and public health and its prevention and control has aroused widespread concern [4]. Routine treatments for EC include surgery, radiotherapy and chemotherapy. Despite advances in diagnostic techniques, the incidence and mortality of EC in China are still high, and the prognosis of a large number of patients is poor [5, 6]. The 5-year overall survival rate is still less than 30% [7], part of the reason may be related to the late diagnosis of most patients with EC [8]. Lacking of specific symptoms and effective treatment goals has created obstacles to the development of new treatment regimens and the improvement of patients’ prognosis. Therefore, a deeper understanding of the molecular mechanism of EC tumorigenesis and identification of new biomarkers are essential to improve the diagnosis and treatment of EC.

The results of the Human Genome Project showed that only 2% of the RNA sequences in the normal human genome could encode proteins, most of which are transcribed into non-coding RNA, including long non-coding RNAs (lncRNAs) and microRNAs [9]. lncRNAs are a kind of non-coding RNAs whose transcriptional length is more than 200 nucleotides. lncRNAs can be divided into sense, antisense, bidirectional, intragenic, and intergenic lncRNAs according to the anatomical characteristics of gene loci. Initially, lncRNAs were regarded as a transcriptional “noise” and were not considered to have biological functions, but then found that they were involved in the regulation of protein coding genes at both transcriptional and epigenetic level [10]. Up to now, more and more evidences have shown that lncRNAs are widely expressed in most organs and tissues, and participate in various cellular biological processes, including regulating transcription and protein activity, exertion of structural or histological roles, altering RNA processing and expression regulation as pre-curators of microRNAs, and participating in chromosomal silencing and modification, etc., which mediate the growth of cancer cells reproductive, invasive and apoptotic processes [11–14]. HOX transcript antisense RNA (HOTAIR) [15], maternal expressed gene 3 (MEG3) [16], urothelial cancer associated factor 1 (UCAI) [17], cancer susceptibility candidate 9 (CASC9) [18], small nucleolar RNA host gene 6 (SNHG6) [19], plasmacytoma variant translocation 1 (PVT1) [20], and HOXA transcript at the distal tip (HOTTIP) [21] were all confirmed to be abnormally expressed in EC. Furthermore, the biological functions of lncRNAs are closely related to microRNAs. MicroRNAs are special non-coding RNA that can be widely observed in eukaryotic organisms. They are ~19-25 nucleotides in length. MicroRNAs are involved in the regulation of cell cycle, differentiation, development, metabolism and aging. At present, there are more than 2,000 specific microRNAs in the human genome. Although they do not have open reading frames and encode proteins, they can complement and pair with the base of the 3’ untranslated region (UTR) of the RNA, which inhibits their translation and regulates the sequential expression of genes in organisms at the transcriptional and post-transcriptional levels, thus, exerting their biological effects [22]. Some lncRNAs can regulate the activity of microRNAs by “sponge” adsorption, thereby affecting the transcription and expression of downstream target genes and participating in the occurrence and development of malignant tumors. These lncRNAs are also known as competitive endogenous RNA (ceRNA). In recent years, some scholars have sorted out the role and application of lncRNAs in EC. Huang et al. [23] summarized the function of lncRNA in EC, focusing on the lncRNA-mediated regulatory mechanism that affects the biological characteristics of EC. Su et al. [24] focused on the regulatory mechanism of lncRNAs in EC and discussed their potential clinical applications as diagnostic and prognostic biomarkers. Yu et al. [25] discussed the role of competitive endogenous RNA networks in ESCC and identified several meaningful lncRNAs related to the prognosis of ESCC. These published literature articles provide basic materials and ideas for the development of this review. However, with the increasing number of studies on lncRNAs-mediated EC, it is necessary to summarize...
the latest research results and further sort out and summarize them. In this review, we intend to review and discuss the involvement of lncRNAs in the progression of EC.

2 | INVOLVEMENT OF lncRNAs IN THE GROWTH OF EC

Escaping proliferation inhibition, resisting apoptosis are the most common biological characteristic of EC cells. Studies have found that abnormal expression of lncRNAs is closely related to the biological behavior of EC cells, such as proliferation, apoptosis and cell cycle abnormalities (Table 1).

2.1 | Promoting proliferation

The growth of normal cells depends on the regulation of growth factors, but EC cells can maintain their ability to continue to proliferate with little or no growth factors. Chen et al. [26] found that the expression of lncRNA SBF2-AS1 was significantly up-regulated in ESCC cells, and the proliferation ability of ESCC was significantly reduced after silencing lncRNA SBF2-AS1. Therefore, lncRNA SBF2-AS1 is considered as a new biomarker in ESCC and potential therapeutic target. Liu et al. [27] found that lncRNA DUXAP8 can promote the proliferation of EC cells and may be an important regulator of EC. In order to determine the biological role of lncRNA DLX6-AS1 in ESCC cells, Tian et al. [28] carried out in vitro functional loss experiments. The transfection of lncRNA DLX6-AS1 targeting oligonucleotides (si-dlx6-as1) was found to hinder the expression of lncRNA DLX6-AS1 in EC9706 and KYSE-520 cells. Compared with negative control group, cell counting kit-8 (CCK-8) assay and colony formation analysis showed that the silencing of lncRNA DLX6-AS1 could significantly inhibit the proliferation of ESCC cells and reduce the number of colony formation, respectively. These results suggested that lncRNA DLX6-AS1 could accelerate the proliferation of ESCC cells in vitro, suggesting that lncRNA DLX6-AS1 played an important role in ESCC. Wu et al. [18] demonstrated that lncRNA CASC9 promoted the proliferation of EC cells by recruiting enhancer of zeste homolog 2 (EZH2) and subsequently changes H3K27me3 level to negatively regulate programmed cell death 4 (PDCD4) expression for the first time. As carcinogenic genes, lncRNA SBF2-AS1, lncRNA DUXAP8, lncRNA DLX6-AS1 and lncRNA CASC9 may be biomarker with diagnostic or prognostic value in ESCC.

2.2 | Inhibiting proliferation

lncRNA LET, also known as NPTN intron transcript 1, is 2606 nucleotides in length and located on chromosome 15q24.1. As the latest identified lncRNA, lncRNA LET is under-expressed in several cancers and used as a tumor inhibitor [29, 30]. Chen et al. [31] investigated the expression, clinical significance and biological role of microRNAs-548k and lncRNA LET in ESCC. Bioinformatics analyses and cell experiments showed that lncRNA LET could inhibit the proliferation of ESCC cells, was a direct target of microRNA-548k, and mediated the carcinogenic effect of microRNA-548k in ESCC. These data indicated that the regulation axis of microRNA-LET could be used as a potential biomarker and therapeutic target in ESCC.

2.3 | Inhibiting apoptosis

Apoptosis is a process of cell death caused by endogenous and exogenous factors triggering the intracellular death program. The infinite growth of EC cells is related to the inhibition of apoptosis, so the apoptosis disorder is closely related to the occurrence of EC. Fan et al. [32] confirmed that lncRNA SNHG6 significantly inhibited ESCC apoptosis. The overexpression of lncRNA PLncRNA-1 was related to the stage of advanced tumors and lymph node metastasis, and it could be a potential prognostic marker and therapeutic target of ESCC. Wang et al. [33] confirmed that lncRNA PLncRNA-1 could inhibit the apoptosis of ESCC cells. In a study by Tian et al. [28], the authors examined the expression and biological role of lncRNA DLX6-AS1 in EC and found that the down-regulation of DLX6-AS1 could accelerate the apoptosis of ESCC cells and affect the expression of apoptosis-related protein B-cell lymphoma-2 (Bcl-2). Moreover, bioinformatics predictions showed that DLX6-AS1 had a binding site of microRNA-99a/100, while microRNA-99a/100 had a mammalian target of rapamycin (mTOR) targeting site. Another study confirmed that microRNA-99a/100 promoted apoptosis by targeting mTOR in human ESCC. [34]. Yoon et al. [35] reported that lncRNA LUCAT1 promoted tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in ESCC. In conclusion, these data suggested that lncRNA DLX6-AS1 and lncRNA lucat1 acted as an oncogene by inhibiting the apoptosis of EC cells.

2.4 | Inducing apoptosis

Contrary to lncRNA and lncRNA LUCAT1, some lncRNAs can induce apoptosis in EC. Huang et al. [36] detected the
| LncRNA     | Pathological type | Sample type | Expression level | Function                                                                 | Molecular mechanism                                                                 | Clinic-pathological correlation                                                                 | Prognosis correlation | Reference |
|------------|------------------|-------------|-----------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------|-----------|
| 91H        | ESCC             | Cell, Tissue| ↓               | Inhibit invasion                                                          | Associate with H19 methylation and inhibit IGF2 expression                              | Negatively correlate with depth of invasion, neoplastic grading and TNM                      | Positive correlation  | [59]      |
| AFAP1-AS1  | EAC, ESCC        | Cell, Tissue| ↑               | Promote proliferation, growth, invasion, migration and chemoradiotherapy resistance; inhibit apoptosis | NA                                                                                    | Positively correlate with lymph node metastasis, distant metastasis, advanced clinical stage and response to radiotherapy | Negative correlation | [51, 60]  |
| AK001796   | ESCC             | Cell, Tissue| ↑               | Promote growth, influence cell cycle                                      | Regulate MDM2/p53 signal pathway                                                      | NA                                                                                         | NA                    | [40]      |
| ATB        | ESCC             | Cell, Tissue| ↑               | Promote proliferation and migration                                       | Dysregulate miR-200b/K2 signaling                                                     | NA                                                                                         | Negative correlation  | [42, 61]  |
| BC032469   | ESCC             | Cell, Tissue| ↑               | Promote proliferation, migration, and invasion; influence cell cycle; inhibit apoptosis. | Regulate HTERT expression                                                              | Positively correlate with lymph node metastasis, TNM stage and tumor size                  | Negative correlation  | [38]      |
| BC200      | ESCC             | Tissue      | ↑               | NA                                                                        | NA                                                                                    | NA                                                                                         | Negative correlation  | [62]      |
| BDNF-AS    | EC               | Cell, Tissue| ↓               | Inhibit proliferation, migration, invasion, EMT                           | Target miR-214                                                                        | NA                                                                                         | NA                    | [63]      |
| CASC2      | ESCC             | Cell        | ↓               | Enhance antitumor activity of cisplatin                                   | Inhibiting miR-181a                                                                   | NA                                                                                         | NA                    | [17]      |

(Continues)
| LncRNA      | Pathological type | Sample type | Expression level | Function                                                                 | Molecular mechanism                                                                 | Clinic-pathological correlation                          | Prognosis correlation | Reference   |
|------------|-------------------|-------------|------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------|------------|
| CASC9      | ESCC              | Cell, Tissue| ↑                | Promote proliferation, migration, invasion; influence cell cycle; inhibit apoptosis | Modulate expression levels of EMT markers; negatively regulate PDCD4 expression      | Positively correlate with tumor size, tumor stage, lymph nodes metastasis, and clinical stage | Negative correlation | [18, 41, 62, 64-66] |
| CCAT1      | ESCC              | Cell        | ↑                | Promote proliferation, migration and adhesion                              | Regulate miR-7/HOXB13 axis                                                          | NA                                                      | NA                     | [67]       |
| CCAT2      | ESCC              | Tissue      | ↑                | NA                                                                         | NA                                                                                   | Correlate with lymph node metastasis, advanced TNM stages | Negative correlation | [68]       |
| CDKN2B-AS1 | EC                | Cell        | ↑                | Promote proliferation                                                      | Inhibit HTERT expression                                                            | NA                                                      | NA                     | [69]       |
| DANCR      | ESCC, EC          | Cell, Tissue| ↑                | Promote proliferation, migration, invasion; inhibit apoptosis              | NA                                                                                   | NA                                                      | NA                     | [70]       |
| DUXAP8     | EC                | Cell, Tissue| ↑                | Promote proliferation, invasion                                            | NA                                                                                   | NA                                                      | NA                     | [27]       |
| ECM        | ESCC              | Cell, Tissue| ↑                | Promote invasion and metastasis                                           | Regulate ICAM-1                                                                     | Positively correlate with lymph node metastasis          | NA                     | [48, 71]  |
| ENST00000508406.1 | ESCC          | Tissue      | ↑                | NA                                                                         | NA                                                                                   | Positively correlate with TNM stages                    | NA                     | [72]       |
| ESCCAL-1   | ESCC              | Tissue      | ↑                | Promote invasion; inhibit apoptosis                                        | NA                                                                                   | NA                                                      | NA                     | [43, 64]  |
| EZR-AS1    | ESCC              | Cell, Tissue| ↑                | Promote migration                                                          | Upregulate EZR expression by causing SMYD3 Redistribution                            | NA                                                      | NA                     | [44]       |
| FAM201A    | ESCC              | Tissue      | ↑                | Reduce radiosensitivity                                                    | Regulate ATM and mTOR Expression via miR-101                                        | NA                                                      | Negative correlation  | [73]       |
| LncRNA   | Pathological type | Sample type | Expression level | Function                                | Molecular mechanism                                      | Clinic-pathological correlation | Prognosis correlation | Reference          |
|---------|-------------------|-------------|------------------|------------------------------------------|----------------------------------------------------------|----------------------------------|----------------------|---------------------|
| FOXCUT  | ESCC              | Cell, Tissue| ↑                | Promote proliferation, Colony formation, migration, invasion | Modulate FOXC1                                            | Positively correlate with poor Differentiation, advanced lymph node classification and metastasis | Negative Correlation   | [74]                |
| GAS5    | ESCC              | Tissue, Serum| ↓                | Inhibit proliferation, migration and invasion | Inactivate the PI3K/PKB/mTOR pathway; feedback loop between GAS5 and the interferon signaling pathway; induce cell cycle arrest at G2/M stage; Influence the expression of EMT-associated proteins | Positively correlate with stage of primary tumor | NA                  | [39-41, 75-77]     |
| H19     | ESCC, EC          | Cell, Tissue| ↑                | Promote proliferation and metastasis     | Regulate G0/G1 phase and epithelial marker; induce EMT    | Positively correlate with tumor depth, clinical stage and lymph node metastasis | Negative correlation   | [48, 78]            |
| HNF1A-AS1 | ESCC, EAC        | Cell, Tissue| ↑                | Promote growth, proliferation, metastasis migration, invasion and angiogenesis; inhibit cell apoptosis | Sponge miR-214 to upregulate the expression of SOX-4; modulate chromatin and nucleosome assembly | NA                      | NA                  | [30, 31, 79, 80]   |

(Continues)
| LncRNA   | Pathological type | Sample type | Expression level | Function                          | Molecular mechanism                                                                 | Clinic-pathological correlation                      | Prognosis correlation   | Reference                  |
|----------|-------------------|-------------|------------------|-----------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------|-------------------------|----------------------------|
| HOTAIR   | EC, ESCC          | Cell, Tissue, Serum | ↑                 | Promote proliferation, invasion, migration and EMT; reduce radioresistance         | Regulate miR-125/HK2 and miR-143/HK2 axis, miR-148a/Snail2 axis, miR-1/CCND1 axis; mediate gene regulation; inhibit WIF-1 expression and activate WNT pathway | Positively correlate with TNM stage                   | Negative correlation   | [32-37, 43, 81–86]         |
| HOTTIP   | ESCC              | tissue, cell  | ↑                 | promote proliferation, Migration and invasion                                     | Induce EMT                                                                          | NA                                                   | NA                      | [21]                       |
| LET      | ESCC              | Tissue, Cell  | ↓                 | Inhibit migration and invasion; promote apoptosis                                  | regulate p53 expression                                                               | Positively correlate with clinical features          | NA                      | [87]                       |
| LINC00173| ESCC              | Cell         | ↓                 | Inhibit proliferation and cell cycle                                              | NA                                                                                  | NA                                                   | NA                      | [88]                       |
| linc00460| ESCC, EC          | Cell, Tissue  | ↑                 | Promote growth, proliferation; inhibit Apoptosis                                  | NA                                                                                  | Positively correlate with TNM stage, lymph node metastasis | Negative correlation | [27, 45, 46, 89]           |
| LINC01234| EC                | Cell         | ↑                 | Promote proliferation, migration and invasion, inhibit apoptosis                  | NA                                                                                  | NA                                                   | NA                      | [90]                       |
| LINC01296| ESCC              | Cell, Tissue  | ↑                 | Promote proliferation, colony formation, migration and invasion                  | Suppress KLF2 expression via interacting EZH2                                          | Positively correlate with TNM stage, lymph node metastasis | Negative correlation | [91]                       |
| LINC01419| ESCC              | Cell, Tissue  | ↑                 | Promote proliferation, inhibit apoptosis, reduce sensitivity to 5-FU               | Promote GSTP1 methylation                                                              | NA                                                   | NA                      | [86]                       |

(Continues)
| LncRNA        | Pathological type | Sample type | Expression level | Function                                      | Molecular mechanism                                         | Clinic-pathological correlation | Prognosis correlation | Reference |
|--------------|------------------|-------------|-----------------|-----------------------------------------------|-------------------------------------------------------------|-------------------|----------------------|-----------|
| LINC01503    | ESCC             | Cell, Tissue | ↑               | Promote proliferation, colony formation, migration and invasion | Activate ERK signaling via MAPK and increase AKT signaling    | NA                 | NA                   | [92]      |
| LncRNA625    | ESCC             | Cell, Tissue | ↑               | Promote proliferation, Invasion, migration    | Upregulate oncogenes and downregulate tumor Suppressor genes | Positively correlate with clinical stages, lymph node metastasis | Negative correlation | [93]      |
| LOC285194    | ESCC             | Tissue      | ↓               | Reduce chemoradiotherapy resistance          | NA                                                           | Positively correlate with tumor size, TNM stage, lymph node metastases and distant Metastases | NA                   | [54]      |
| MALAT1       | ESCC             | Tissue, Cell | ↑               | Promote proliferation, cell cycle, migration and Invasion | Upregulate p21 and p27 expression, Posttranscriptional regulation | Positively correlate with clinical stages, primary tumor size, and lymph node Metastasis | Negative correlation | [39, 94, 95] |
| NEAT1        | ESCC             | Tissue, Cell | ↑               | Promote proliferation, foci formation, viability, migration, and invasion | Regulate miR-129/CTBP2 axis                                  | Positively correlate with tumor size, lymph node metastasis and clinical stage | Negative correlation | [47, 48, 96, 97] |
| NMR          | ESCC             | Tissue, Cell | ↑               | Promote migration and invasion; inhibit apoptosis; Increase drug resistance | Interact with BPTF and recruits it to chromatin, Upregulate expression of MMP-3 and MMP-10 via ERK1/2 activation | Positively correlate tumor metastasis                      | Negative correlation | [98]      |
| NR_037652.1  | ESCC             | Tissue      | ↑               | NA                                            | NA                                                           | Positively correlate with TNM stage                        | NA                   | [72]      |

(Continues)
| LncRNA      | Pathological type | Sample type | Expression level | Function                         | Molecular mechanism                      | Clinic-pathological correlation | Prognosis correlation | Reference |
|-------------|-------------------|-------------|------------------|-----------------------------------|------------------------------------------|-----------------------------------|-----------------------|-----------|
| PART1       | ESCC              | Cell        | ↑                | Reduce gefitinib resistance       | Through miR-129/Bcl-2 pathway            | NA                                | NA                    | [57]      |
| PAX9        | ESCC              | Tissue      | ↓                | NA                                | NA                                       | NA                                | positive correlation   | [99]      |
| PCAT-1      | ESCC              | Tissue      | ↑                | NA                                | NA                                       | Positively correlate with clinical stage, tumor invasion, lymph node metastasis | Negative correlation      | [100]     |
| POU5F1B     | EC                | Cell        | ↑                | Reduce radiosensitivity            | NA                                       | NA                                | NA                    | [101]     |
| PVT1        | EC                | Cell        | ↑                | Promote invasion and metastasis   | Induce EMT by regulating expression of EMT markers | Positively correlate with tumor stage and metastasis | NA                    | [20]      |
| SBF2-AS1    | ESCC              | Tissue, Cell| ↑                | Promote proliferation and invasion| Bind with PRC2 and guide PRC2 to the promoter of CDKN1A and decrease CDKN1A expression | Positively correlate with tumor size and TNM stage | NA                    | [26, 49] |
| SNHG1       | ESCC              | Tissue, Cell| ↑                | Promote proliferation, invasion and EMT | Down-regulate E-cadherin and up-regulate Vimentin and N-cadherin | Positively correlate with TNM stage, depth of invasion, lymph node metastasis | NA                    | [102]     |
| SNHG6       | ESCC              | Tissue, Cell| ↑                | Promote proliferation, migration and invasion | NA                                       | Positively correlate with TNM stage, lymph node metastasis, distant metastasis | Negative correlation      | [102, 103]|

(Continues)
| LncRNA     | Pathological type | Sample type     | Expression level | Function                                      | Molecular mechanism                                                                                   | Clinic-pathological correlation                      | Prognosis correlation                | Reference                  |
|------------|------------------|-----------------|-----------------|-----------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------|-------------------------------------|---------------------------|
| SOX2OT     | ESCC             | Tissue, Cell    | ↑               | Promote growth, proliferation; antagonize Effect of DDP | NA                                                                                                    | NA                                                  | NA                                  | [38, 104]                 |
| SPRY4-IT1  | ESCC             | Tissue, Cell    | ↑               | Promote growth, proliferation, invasiveness and migration | NA                                                                                                    | Positively correlate with clinical stage            | Negative correlation              | [105]                     |
| TTN-AS1    | ESCC             | Cell, Tissue    | ↑               | Promote proliferation and Metastasis           | Promote expression of Snail1 by binding miR-133b, result in EMT cascade, induce FSCN1 expression by sponging miR-133b and regulate of mRNA-stabilizing protein | NA                                                  | Negative correlation              | [49]                      |
| TUG1       | ESCC             | Tissue, Cell    | ↑               | Promote cisplatin resistance                   | NA                                                                                                    | NA                                                  | Negative correlation              | [44]                      |
| TUSC2P     | ESCC             | Tissue          | ↓               | Inhibit proliferation, invasion; promote apoptosis | Alter expression of TUSC2                                                                             | NA                                                  | Positive correlation              | [106]                     |
| TUSC7      | ESCC             | Cell, Tissue    | ↓               | Inhibit proliferation, colony formation; promote apoptosis and chemotherapy Resistance             | Downregulate miR-224                                                                                  | NA                                                  | Positive correlation              | [107]                     |
| UCA1       | ESCC, EC         | Cell, Tissue    | ↑               | Promote proliferation, migration and invasion  | Regulate miR-204/Sox4 axis                                                                            | Positively correlate with clinical stage            | Negative correlation              | [16, 21, 50, 51, 108, 109] |
| ZEB1-AS1   | ESCC             | Tissue          | ↑               | NA                                            | NA                                                                                                    | Positively correlate with tumor grade, invasion depth and lymph node metastasis | Negative correlation              | [110]                     |

Abbreviations: lncRNA, long non-coding RNA; ESCC, esophageal squamous cell carcinoma; EC, esophageal cancer; EAC, esophageal adenocarcinoma; NA, not available; ↑, upregulation; ↓, downregulation; EMT, epithelial–mesenchymal transition; 5-FU, fluorouracil; DDP, cisplatin.
expression level of IncRNA MEG3 in 28 cases of ESCC and adjacent tissues, and found that the expression of maternally expressed gene 3 (MEG3) in cancer tissues was significantly reduced. Further studies showed that MEG3 could induce the apoptosis of cancer cells. Lv et al. [37] reported that the expression of IncRNA MEG3 was down-regulated in ESCC, which could activate p53 and induce the apoptosis of cancer cells. It can be seen that IncRNA MEG3 is involved in regulating the apoptosis of EC cells.

### 2.5 Affecting cell cycle

Abnormal regulation of tumor cell proliferation is the result of disordered control of cell cycle correction points. This disorder is secondary to abnormalities in genes that regulate cell cycle correction points or mutations or abnormal expression of oncogenes or tumor suppressor genes that encode proteins in the transmembrane signal transduction pathway that control cell proliferation. Lu et al. [38] reported that the knockout of IncRNA BC032469 in TE13 and ECA109 cells could induce cell cycle arrest at the G0/G1 phase. Cell cycle analysis showed that inhibiting the expression of IncRNA CASC9 resulted in cell cycle arrest in G1 phase of cancer cells KYSE450 and KYSE150 and decrease in the proportion of S phase cells [18]. In view of the fact that IncRNA MALAT1 significantly promotes ESCC cell growth in vitro and in vivo, Hu et al. [39] confirmed that inhibiting IncRNA MALAT1 might activate ATM-CHK2 pathway in EC cells and ultimately led to G2/M stagnation in EC. There are growing evidence that HOXA transcripts at the distal tip (HOTTIP) of the 5'end are dysfunctional in various cancers. Chen et al. [26] found that IncRNA SBF2-AS1 could be related to the cell cycle of EC and could affect the G2 phase transition of ECA109 cells through reducing the expression of cyclin-dependent kinase inhibitor 1A (CDKN1A). It can be seen from the above research that IncRNAs mediate the abnormal cycle of EC cells.

### 3 THE INVOLVEMENT OF IncRNAs IN THE INVASION AND METASTASIS OF EC

#### 3.1 Promoting invasion and metastasis

Tumor cell invasion and metastasis is a complex process, which is affected by many factors, such as microenvironment, host cells, genes, signal molecules and so on. Liu et al. [40] found that IncRNA AK001797 could regulate ESCC cell growth and cell cycle by activating murine double minute 2 (MDM2)/p53 signal, significantly increased the proportion of S-phase ESCC cells and reduced the proportion of G2/M phase ESCC cells. Pan et al. [41] studied the expression and function of IncRNA CASC9 in ESCC. They found that the expression of IncRNA CASC9 was significantly up-regulated in ESCC tissues. In addition, the knockout of IncRNA CASC9 significantly inhibited the migration and invasion of ESCC cells, suggesting that IncRNA CASC9 might be a new marker of poor prognosis of EC and a potential therapeutic target for intervention of EC. Tian et al. [28] conducted the experiments to explore the effect of IncRNA DLX6-AS1 on the invasion of ESCC cells. Transwell invasion experiment showed that the number of invasive cells in the IncRNA DLX6-AS1 knockout group was lower than that in the control group in ESCC cell lines (EC9706 and KYSE-520). Western blot analysis showed that the levels of mTOR, Bcl-2 and matrix metalloproteinase-2 (MMP-2) in ESCC cell lines were lower than those in the control group. Therefore, these data suggested that IncRNA DLX6-AS1 could promote the invasion of ESCC cells. In order to study the biological function of IncRNA SNHG6 in ESCC, Zhang et al. [19] introduced si-SNHG6 into EC109 and EC1 cells to inhibit the expression of IncRNA SNHG6. The results showed that the expression of small nuclear RNA host gene 6 (SNHG6) significantly decreased after transfection with si-SNHG6-1 and si-SNHG6-2. The silencing efficiency in EC109 was 75.4% and 77.3%, respectively, and in EC1 was 80.8% and 79.4%, respectively. The transwell assay result showed that IncRNA SNHG6 could enhance the migration ability of EC109 and EC1 cells. Compared with the si-NC group, the numbers of migrating cells in the si-SNHG6-1 and si-SNHG6-2 groups were significantly decreased. At the same time, compared with the si-NC group, the invasive ability of the si-SNHG6-1 and si-SNHG6-2 groups was significantly inhibited. These results suggested that IncRNA SNHG6 might play a carcinogenic role in ESCC. Lu et al. [38] used real-time quantitative reverse transcription-polymerase chain reaction to detect the specific differential expression of IncRNA BC032469 in ESCC and evaluated the role of IncRNA BC032469 in the occurrence and development of EC by silencing and overexpressing IncRNA in vitro and in vivo. The results showed that the expression level of IncRNA BC032469 in ESCC was higher than that in corresponding non-cancerous tissues, while knockout of low IncRNA BC032469 inhibited the migration and invasion of EC cells. Western blotting analysis showed that IncRNA BC032469 could regulate the expression of human telomerase reverse transcriptase (hTERT), which is very important for cell invasion and metastasis. In addition, the restored expression of hTERT protein could weaken the inhibition of IncRNA BC032469 on ESCC cells. In conclusion, these results showed that IncRNA-BC032469 was a carcinogenic IncRNA that promoted cancer progression. Yoon et al. [35] transfected KYSE-30 cells and HCE-4 cells...
with si-LUCAT1, and then determined wound healing and invasion. It was noteworthy that si-LUCAT1 significantly inhibited wound closure compared with cells transfected with si-NC. The invasion of KYSE-30 cells and HCE-4 cells was also significantly reduced by transfection with IncRNA LUCAT1 small interfering RNA (si-LUCAT1). These effects of LUCAT1 siRNA were significantly blocked by pcDNA-LUCAT1 transfection. Meanwhile, transfection of si-LUCAT1 reduced the expression of N-cadherin, snail and Zinc finger E-box binding homeobox-1 (ZEB1), while the expression of E-cadherin increased. Overexpression of IncRNA LUCAT1 could reverse these changes suggesting that IncRNA LUCAT1 was involved in the invasion and migration of EC cells. Further studies have shown that this was related to the ubiquitination of DNA methyltransferase 1 (DNMT1) regulated by IncRNA LUCAT1.

LncRNA HOTAIR is a 2158 NT long IncRNA in the human genome. It is located between HoxC11 and HoxC12 genes on chromosome 12 and regulates the Hox gene family [42]. It has been reported that IncRNA HOTAIR can also inhibit the expression of WNT inhibitory factor 1 (WIF-1) in ESCC by binding with polycomb repressive complex 2 (PRC2) complex, and then activate histone and Wnt/β-catenin pathways in H3K27 promoter region [43]. Chen et al. [15] also reported that the expression of lncRNA HOTAIR was significantly higher in EC than in adjacent non-cancerous tissues band multivariate analysis showed that the expression of lncRNA HOTAIR was an independent prognostic factor for lymph node metastasis. It can be seen from the above that LncRNA AK001797, IncRNA CASC9, IncRNA DLX6-AS1 and other lncRNAs promote the invasion and metastasis of EC cells through different mechanisms.

### 3.2 Inhibiting invasion and metastasis

Metastasis and spread are one of the reasons why EC is difficult to cure, and certain IncRNAs can effectively inhibit the invasion and metastasis of EC cells. Zhang et al. [44] showed that antisense lncRNA EZR-AS1 was positively correlated with ezrin (EZR) expression in ESCC tissues and cell lines. LncRNA EZR-AS1 promotes cell migration by up-regulating EZR expression. In mechanism, antisense IncRNA EZR-AS1 forms a complex with RNA polymerase II to activate EZR transcription. In addition, IncRNA EZR-AS1 can also recruit SET and MYND domain-containing protein 3 (SMYD3) to binding sites in GC-rich regions downstream of EZR promoter to promote their binding. The interaction between IncRNA EZR-AS1 and SMYD3 can further enhance the transcription and expression of EZR, suggesting that IncRNA EZR-AS1, as a member of RNA polymerase complex, plays an important role in inhibiting the invasion of EC cells by inhibiting SMYD3-dependent H3K4 methylation. These results showed that IncRNAs inhibited EC cells invasion and metastasis through affecting related gene expression.

### 3.3 Epithelial-mesenchymal transition (EMT)

EMT plays an important role in the invasion of various types of cancer by transforming adherent and polarized epithelial cells into invasive and active mesenchymal cells [45]. Transcription factors, such as Twist and Snail in EMT, can increase the expression level of interstitial markers and decrease the expression of epithelial markers. The rupture of tight junctions can lead to the loss of epithelial markers and the acquisition of mesenchymal markers [46]. The expression level of IncRNA FAL1 in ESCC cell lines was found to increase abnormally. Knockout of IncRNA FAL1 inhibited cell invasion and EMT by affecting related genes, while overexpression of IncRNA FAL1 had the opposite effect, suggesting that IncRNA FAL1 could promote the invasion of EC cells [47]. Huang et al. [48] found that IncRNA H19 might be involved in the regulation of EMT marker expression in EC cell lines. Lin et al. [49] studied the role of IncRNA HOTTIP in ESCC and observed that IncRNA HOTTIP was up-regulated in ESCC and promoted cell metastasis in vivo and in vitro. Interestingly, as a molecular sponge, IncRNA HOTTIP has the binding site of microRNA-30b, which can regulate the level of microRNA-30b in nucleus and cytoplasm, thus mediating the inhibition of HOXA13. In addition, IncRNA HOTTIP upregulates Snail 1 through competitively binding to microRNA-30b, and then promotes EMT and invasion. Therefore, one of the pathways of IncRNAs mediated the development of EC is to affect the EMT process.

### 4 THE INVOLVEMENT OF IncRNAs IN THE DRUG RESISTANCE OF EC

Chemoradiotherapy is an important method for the treatment of EC. However, with the prolongation of treatment time, EC cells could become less sensitive to chemoradiotherapy, and even develop resistance to drugs or radiotherapy schemes. This phenomenon is called drug resistance, including primary and acquired resistance, is one of the most difficult and complex problems in the treatment of malignant tumors. Lin et al. [50] reported that IncRNA LINC0261 could induce the chemosensitivity of EC cells to fluorouracil (5-FU) by regulating methylation-dependent inhibition of dihydropyrimidine dehydrogenase in human EC. But there are many other studies have confirmed that
most of the lncRNA could enhance the resistance of EC to radiotherapy and chemotherapy. Zhou et al. [51] reported that the expression of lncRNAs AFAP1-AS1, UCA1 and HOTAIR in cisplatin-resistant EC cells was imbalanced compared with their parent cells. Jiang et al. [52] found that the expression level of lncRNA TUG1 in ESCC tissues was significantly higher than that of matched adjacent normal tissues, and the high expression of lncRNA TUG1 was significantly correlated with chemotherapy resistance. Subsequent survival analysis showed that the prognosis of patients with high expression of lncRNA TUG1 was poor, especially for well-differentiated and moderate, ulcerative, small size and chemo-sensitive tumors. Compared with normal adjacent tissues, the expression of lncRNA PCAT-1 was higher in EC, especially in secondary EC. Overexpression of lncRNA PCAT-1 could increase the proliferation rate and growth of EC cells, and reduce the chemical sensitivity of cells to cisplatin, which showed that lncRNA PCAT-1 promoted the development of EC and inhibited the sensitivity of EC to cisplatin [53]. Tong et al. [54] used quantitative real-time polymerase chain reaction to detect the expression of lncRNA LOC285194 in biopsy specimens and matched normal tissues of ESCC patients who underwent surgery or resection after preoperative radiotherapy. Then, the relationship between the expression of lncRNA LOC285194 and clinicopathological features and prognosis was analyzed. The data showed that the expression of lncRNA LOC285194 in ESCC tumors was significantly lower than that in adjacent normal tissues. The complete remission rate was 57% in the group with high expression of lncRNA LOC285194 and 15% in the group with low expression of lncRNA LOC285194. Univariate analyses showed that low expression of lncRNA LOC285194 was significantly correlated with the response to radiotherapy and chemotherapy. In addition, Kaplan-Meier survival analysis showed that the disease-free survival rate and overall survival rate of patients with low expression of lncRNA LOC285194 decreased. Multivariate analysis further confirmed that the low expression of lncRNA LOC285194 was an independent prognostic factor for chemoradiotherapy. Drug transporter-mediated drug resistance is one of the mechanisms of drug resistance. Excitatory transporters are highly expressed in most drug-resistant cells, such as P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), multidrug resistance protein 2 (MRP2), breast cancer resistance protein (BCRP) and more. They can excrete different kinds of chemotherapeutic drugs from cells, resulting in the reduction of intracellular drug concentration, thereby reducing the toxicity of drugs to cancer cells [55, 56]. At present, resistance to gefitinib and other anti-tyrosine kinase inhibitors has become a major obstacle to improve the clinical prognosis of patients with advanced metastasis of ESCC. Although lncRNA can regulate the biological behavior of EC cells, the role of lncRNA on drug efflux transporters in cells has not been fully elucidated. Therefore, Kang et al. [57] studied the potential role of lncRNA in the formation of chemoresistance in human EC. They found that compared with parental ESCC cells, LncRNA PART1 up-regulated signal transducer and activator of transcription 1 (STAT1) in gefitinib-resistant cells, in which STAT1 could bind to the promoter region of LncRNA PART1, leading to its activation. Inhibition of LncRNA PART1 effectively promotes gefitinib-induced cell death, while increase of LncRNA PART1 promotes gefitinib resistance and Bcl-2 expression in EC cells by competitive binding to microRNA-129[57]. In addition, extracellular LncRNA PART1 was shown to incorporate exosomes and enhance the resistance of other cells to gefitinib. Chen et al. [58] found that the high expression of LncRNA VLDLR and LncRNA ABCG2 genes affected the formation of drug resistance in EC. Extracellular vesicles released by drug-resistant cells can up-regulate the expression of LncRNA ABCG2 in EC cells, thus regulating the drug resistance of EC cells. These results suggested that the abnormal expression of lncRNAs was associated with chemosensitivity of EC and may be helpful to predict the poor prognosis of EC.

5 | CONCLUSION

In conclusion, the abnormal expressions of lncRNAs affect the proliferation, apoptosis, invasion, metastasis, and drug resistance of EC cells through related genes or signaling pathways, which provides new approaches for the diagnosis, targeted therapy and evaluation of therapeutic effect of EC (Table 1). However, the research on lncRNA is still lacking in depth. With the continuous application of new technologies, the understanding of the mechanism of lncRNAs in EC will become more and more complete and accurate. Just as lncRNAs play multiple roles in EC, lncRNAs are expected to become a new diagnostic, drug resistance and prognostic indicator of EC.

DECLARATIONS
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT FOR PUBLICATION
Not applicable.

AVAILABILITY OF DATA AND MATERIALS
Not applicable.
COMPETING INTERESTS
The authors declare that they have no competing interests.

FUNDING
This study was supported by the Natural Science Foundation of Henan Province of China (202300410460); Henan Province Medical Science and Technology Research Project Joint Construction Project (Grant No. LHGJ20190003, LHGJ20190055); the National Natural Science Foundation of China (Grant No. 31670895).

AUTHORS’ CONTRIBUTIONS
WHX, YYZ and ZBS contributed substantially to the conception of the review. WHX, LFL and ZJZ searched for document materials and extract information. WHX, BWB, YKZ and ZRF wrote the original draft. JZ, QCK and YKZ revised the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS
Not applicable.

ORCID
Jie Zhao https://orcid.org/0000-0003-1168-8384

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.21590
2. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39(1):22. https://doi.org/10.1186/s40880-019-0368-6
3. Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210-5. https://doi.org/10.1016/j.ajjsur.2016.10.005
4. Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23(4):233-42. https://doi.org/10.2188/jea.je20120162
5. Chen W, Zheng R, Zhang S, Zeng H, Fan Y, Qiao Y, et al. Esophageal cancer incidence and mortality in China, 2010. Thorac Cancer. 2014;5(4):343-8. https://doi.org/10.1111/1759-7714.12100
6. Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019;39(1):79. https://doi.org/10.1186/s40880-019-0427-z
7. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010;127(1):138-47. https://doi.org/10.1002/ijc.25031
8. Alsop BR, Sharma P. Esophageal Cancer. Gastroenterol Clin North Am. 2016;45(3):399-412. https://doi.org/10.1016/j.gtc.2016.04.001
9. Ferlita A, Battaglia R, Andronico F, Caruso S, Cianci A, Purrello M, et al. Non-Coding RNAs in Endometrial Physiopathology. Int J Mol Sci. 2018;19(7). https://doi.org/10.3390/ijms19072120
10. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629-41. https://doi.org/10.1016/j.cell.2009.02.006
11. De Paepe B, Lefever S, Mestdagh P. How long noncoding RNAs enforce their will on mitochondrial activity: regulation of mitochondrial respiration, reactive oxygen species production, apoptosis, and metabolic reprogramming in cancer. Curr Genet. 2018;64(1):163-72. https://doi.org/10.1007/s00294-017-0744-1
12. Yu J, Jiang L, Gao Y, Sun Q, Liu B, Hu Y, et al. LncRNA CCATI negatively regulates miR-181a-5p to promote endometrial carcinoma cell proliferation and migration. Exp Ther Med. 2019;17(5):4259-66. https://doi.org/10.3892/etm.2019.7422
13. Tan YT, Lin JF, Li T, Li JJ, Xu RH, Ju HQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2020. https://doi.org/10.1007/s10555-020-12108
14. Luo J, Langer LF, Liu J. A novel role of LncRNA in regulating tumor metabolism and angiogenesis under hypoxia. Cancer Commun (Lond). 2019;39(1):2. https://doi.org/10.1186/s40880-019-0348-x
15. Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, et al. Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog. 2013;52(11):908-15. https://doi.org/10.1002/mc.21944
16. Jiao C, Song Z, Chen J, Zhong J, Cai W, Tian S, et al. LncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncol Rep. 2016;36(5):2960-6. https://doi.org/10.3892/or.2016.5121
17. Zhu D, Yu Y, Qi Y, Wu K, Liu D, Yang Y, et al. Long Non-coding RNA CASC2 Enhances the Antitumor Activity of Cisplatin Through Suppressing the Akt Pathway by Inhibition of miR-181a in Esophageal Squamous Cell Carcinoma Cells. Front Oncol. 2019;9:350. https://doi.org/10.3389/onc.2019.00350
18. Wu Y, Hu L, Liang Y, Li J, Wang K, Chen X, et al. Up-regulation of LncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer. 2017;16(1):150. https://doi.org/10.1186/s12943-017-0715-7
19. Zhang Y, Li R, Ding X, Zhang K, Qin W. Upregulation of long non-coding RNA SNHG6 promote esophageal squamous cell carcinoma cell malignancy and its diagnostic value. Am J Transl Res. 2019;11(2):1084-91
20. Zheng X, Hu L, Li S. High expression of IncRNA PVT1 promotes invasion by inducing epithelial-to-mesenchymal transition in esophageal cancer. Oncol Lett. 2016;12(4):2357-62. https://doi.org/10.3892/ol.2016.5026
21. Lin C, Wang Y, Wang Y, Zhang S, Yu L, Guo C, et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells. Oncogene. 2017;36(38):5392-406. https://doi.org/10.1038/onc.2017.133
22. Liu G, Li B. Role of miRNA in transformation from normal tissue to colorectal adenoma and cancer. J Cancer Res Ther. 2019;15(2):278-85. https://doi.org/10.4103/jcrt.JCRT_135_18
23. Huang X, Zhou X, Hu Q, Sun B, Deng M, Qi X, et al. Advances in esophageal cancer: A new perspective on pathogenesis associated with long non-coding RNAs. Cancer Lett. 2018;413:94-101. https://doi.org/10.1016/j.canlet.2017.10.046

24. Su M, Xiao Y, Ma J, Cao D, Zhou Y, Wang H, et al. Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications. J Hematol Oncol. 2018;11(1):118. https://doi.org/10.1186/s12054-018-0663-8

25. Yu D, Ruan X, Huang J, Hu W, Chen C, Xu Y, et al. Comprehensive Analysis of Competitive Endogenous RNAs Network, Being Associated With Esophageal Squamous Cell Carcinoma and Its Emerging Role in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019;9:1474. https://doi.org/10.3389/fonc.2019.01474

26. Chen R, Xia W, Wang X, Qiu M, Yin R, Wang S, et al. Upregulated long non-coding RNA SBF2-AS1 promotes proliferation in esophageal squamous cell carcinoma. Oncol Lett. 2018;15(4):5071-80. https://doi.org/10.3892/ol.2018.7968

27. Liu W, Zhang Y, Chen M, Shi L, Xu L, Zou X. A genome-wide analysis of long noncoding RNA profile identifies differentially expressed lncRNAs associated with Esophageal cancer. Cancer Med. 2018;7(8):4181-9. https://doi.org/10.1002/cam4.1536

28. Tian W, Jiang C, Huang Z, Xu D, Zheng S. Comprehensive analysis of dysregulated lncRNAs, miRNAs and mRNAs with associated ceRNA network in esophageal squamous cell carcinoma. Gene. 2019;696:206-18. https://doi.org/10.1016/j.gene.2019.02.051

29. Liu B, Pan CF, He ZC, Wang J, Wang PL, Ma T, et al. Long Non-coding RNA-LET Suppresses Tumor Growth and EMT in Lung Adenocarcinoma. Biomed Res Int. 2016;2016:4693471. https://doi.org/10.1155/2016/4693471

30. Ma MZ, Kong X, Weng MZ, Zhang MD, Qin YY, Gong W, et al. Long non-coding RNA-LET is a positive prognostic factor and exhibits tumor-suppressive activity in gallbladder cancer. Mol Carcinog. 2015;54(11):1397-406. https://doi.org/10.1002/ma.22215

31. Chen Z, Lin J, Wu S, Xu C, Chen F, Huang Z. Up-regulated miR-548k promotes esophageal squamous cell carcinoma progression via targeting long noncoding RNA-LET. Exp Cell Res. 2018;362(1):90-101. https://doi.org/10.1016/j.yexcr.2017.11.006

32. Fan RH, Guo JN, Yan W, Huang MD, Zhu CL, Yin YM, et al. Small nucleolar host gene 6 promotes epithelial-mesenchymal transition and protein expression in gallbladder cancer. Mol Carcinog. 2015;54(11):1397-406. https://doi.org/10.1002/mc.22215

33. Chen Z, Lin J, Wu S, Xu C, Chen F, Huang Z. Up-regulated miR-548k promotes esophageal squamous cell carcinoma progression via targeting long noncoding RNA-LET. Exp Cell Res. 2018;362(1):90-101. https://doi.org/10.1016/j.yexcr.2017.11.006

34. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol. 2013;30(1):411. https://doi.org/10.1007/s12032-012-0411-9

35. Yoon JH, You BH, Park CH, Kim YJ, Nam JW, Lee SK. The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma. Cancer Lett. 2018;417:47-57. https://doi.org/10.1016/j.canlet.2017.12.016

36. Huang ZL, Chen RP, Zhou XT, Zhan HL, Hu MM, Liu B, et al. Long non-coding RNA MEG3 induces cell apoptosis and proliferation in esophageal cancer through endoplasmic reticulum stress. Oncol Rep. 2017;37(5):3093-9. https://doi.org/10.3892/or.2017.5568

37. Lv D, Sun R, Yu Q, Zhang X. The long non-coding RNA maternally expressed gene 3 activates p53 and is downregulated in esophageal squamous cell cancer. Tumour Biol. 2016. https://doi.org/10.1007/s13277-016-5426-y

38. Lu C, Yang L, Chen H, Shan Z. Upregulated long non-coding RNA BC032469 enhances carcinogenesis and metastasis of esophageal squamous cell carcinoma through regulating hTERT expression. Tumour Biol. 2016. https://doi.org/10.1007/s13277-016-5428-9

39. Hu L, Wu Y, Tan D, Meng H, Wang K, Bai Y, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2015;34:7. https://doi.org/10.1186/s13046-015-0123-z

40. Liu B, Pan CF, Yao GL, Wei K, Xia Y, Chen YJ. The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. Cancer Cell Int. 2018;18:38. https://doi.org/10.1186/s12935-018-0537-8

41. Pan Z, Mao W, Bao Y, Zhang M, Su X, Xu X. The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer. Cancer Med. 2016;5(9):2442-7. https://doi.org/10.1002/cam4.770

42. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu B, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311-23. https://doi.org/10.1016/j.cell.2007.05.022

43. Ge X, Ma JJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, et al. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci. 2013;104(12):1675-82. https://doi.org/10.1111/j.1349-7006.2013.02296

44. Zhang XD, Huang GW, Xie YH, He JZ, Guo JC, Xu XE, et al. The interaction of lncRNA EZR-AS1 with SMYD3 regulates expression of EZR in ESCC cells. Nucleic Acids Res. 2018;46(4):1793-809. https://doi.org/10.1093/nar/ggx1295

45. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Cell Res. 2019;24(2):520-31. https://doi.org/10.1186/s13046-015-0123-z

46. Dong H, Xie L, Tang C, Chen S, Liu Q, Zhang Q, et al. Snail1 finally expressed gene 3 activates p53 and is downregulated in esophageal squamous cell cancer. Clin Transl Oncol. 2015;17(9):983-9. https://doi.org/10.1007/s12094-015-1149-3

47. Yang Z, Liu D, Wu D, Liu F, Liu C. The biological function of HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits TERT expression. Tumour Biol. 2016. https://doi.org/10.1007/s13277-016-5426-y

48. Huang C, Cao L, Qiu L, Dai X, Ma L, Zhou Y, et al. Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer. Oncol Lett. 2015;10(1):291-6. https://doi.org/10.3892/ol.2015.3165
49. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, et al. Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin Cancer Res. 2018;24(2):486-98. https://doi.org/10.1158/1078-0432.CCR-17-1851

50. Lin K, Jiang H, Zhuang SS, Qin YS, Qiu GD, She QY, et al. Long noncoding RNA LINC00261 induces chemoresistance to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer. FASEB J. 2019;33(2):1972-88. https://doi.org/10.1096/fj.201800759R

51. Zhou XL, Wang WW, Zhu WG, Yu CH, Tao GZ, Wu QQ, et al. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Mol Carcinog. 2016;55(12):2095-105. https://doi.org/10.1002/mc.22454

52. Jiang L, Wang W, Li G, Sun C, Ren Z, Sheng H, et al. High TUG1 expression is associated with chemoresistance and poor prognosis in esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2016;78(2):333-9. https://doi.org/10.1007/s00280-016-3066-y

53. Zhen Q, Gao LN, Wang RF, Chu WW, Zhang YX, Zhao XJ, et al. LncRNA PCAT-1 promotes tumour growth and chemoresistance of esophageal cancer to cisplatin. Cell Biochem Funct. 2018;36(1):27-33. https://doi.org/10.1002/cbf.3314

54. Tong YS, Zhou XL, Wang XW, Wu QQ, Yang TX, Lv J, et al. Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med. 2014;12:233. https://doi.org/10.1186/s12967-014-0233-y

55. Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620-9. https://doi.org/10.1016/j.ijbiomac.2017.10.154

56. Miyata E, Takahashi R, Nishiyama Y, Ito K, Sunada H, Toh Y, et al. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res. 2018;37(1):171. https://doi.org/10.1186/s13046-018-0845-9

57. Kang M, Ren M, Li Y, Fu Y, Deng M, Li C. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res. 2018;37(1):171. https://doi.org/10.1186/s13046-018-0845-9

58. Chen Y, Liu L, Li J, Du Y, Wang J, Liu J. Effects of long non-coding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract. 2019;215(3):470-7. https://doi.org/10.1016/j.prp.2018.12.033

59. Gao T, He B, Pan Y, Xu Y, Li R, Deng Q, et al. Long non-coding RNA 91H contributes to the occurrence and progress of esophageal squamous cell carcinoma by inhibiting IGF2 expression. Mol Carcinog. 2015;54(5):359-67. https://doi.org/10.1002/mc.22106

60. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2013;144(5):596-66.e4. https://doi.org/10.1053/j.gastro.2013.03.019

61. Li Z, Wu X, Gu L, Shen Q, Luo W, Deng C, et al. Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. Cell Death Dis. 2017;8(6):e2888. https://doi.org/10.1038/cddis.2017.245

62. Zhao RH, Zhu CH, Li XK, Cao W, Zong H, Cao XG, et al. BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients. Onco Targets Ther. 2016;9:2221-6. https://doi.org/10.2147/OTT.S99401

63. Zhao H, Diao C, Wang X, Xie Y, Liu Y, Gao X, et al. LncRNA BDNF-AS inhibits proliferation, migration, invasion and EMT in esophageal cancer cells by targeting miR-214. J Cell Mol Med. 2018. https://doi.org/10.1111/jcmm.13558

64. Hao Y, Wu W, Shi F, Dalmolin RJ, Yan M, Tian F, et al. Prediction of long noncoding RNA functions with co-expression network in esophageal squamous cell carcinoma. BMC Cancer. 2015;15:168. https://doi.org/10.1186/s12885-015-1179-z

65. Liang Y, Chen X, Wu Y, Li J, Zhang S, Wang K, et al. LncRNA CAS9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ. 2018;25(11):1980-95. https://doi.org/10.1038/s41418-018-0084-9

66. Gao GD, Liu XY, Lin Y, Liu HF, Zhang GJ. LncRNA CASC9 promotes tumorigenesis by affecting EMT and predicts poor prognosis in esophageal squamous cell cancer. Eur Rev Med Pharmacol Sci. 2018;22(2):422-9. https://doi.org/10.26355/eurrev_201801_14191

67. Zhang E, Han L, Yin D, He X, Hong L, Si X, et al. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 2017;45(6):3086-101. https://doi.org/10.1093/nar/gkw1247

68. Zhang X, Xu Y, He C, Guo X, Zhang J, He C, et al. Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2015;111(7):834-9. https://doi.org/10.1002/jso.23888

69. Hu Z, Wu H, Li Y, Hou Q, Wang Y, Li S, et al. beta-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression. Anticancer Drugs. 2015;26(5):531-9. https://doi.org/10.1097/CAD.0000000000000216

70. Shi H, Shi J, Zhang Y, Guan C, Zhu J, Wang F, et al. Long non-coding RNA DANCER promotes cell proliferation, migration, invasion and resistance to apoptosis in esophageal cancer. J Thorac Dis. 2018;10(5):2573-82. https://doi.org/10.21037/jtd.2018.04.10971

71. Yao J, Shen X, Li H, Xu J, Shao S, Huang JX, et al. LncRNA-ECM is overexpressed in esophageal squamous cell carcinoma and promotes tumor metastasis. Oncol Lett. 2018;16(3):3935-42. https://doi.org/10.3892/ol.2018.9130

72. Wang J, Sun D, Wu K, Liu J, Zhao M, Li X, et al. Genome-wide analysis of long non-coding RNAs in esophageal squamous cell carcinoma reveals their potential role in invasion and metastasis. Thorac Cancer. 2019;10(1):78-89. https://doi.org/10.1111/1759-7714.12904
73. Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, et al. Long Noncoding RNA FAM20A Mediates the Radiosensitivity of Esophageal Squamous Cell Cancer by Regulating ATM and mTOR Expression via miR-101. Front Genet. 2018;9:61. https://doi.org/10.3389/fgene.2018.00611

74. Pan F, Yao J, Chen Y, Zhou C, Geng P, Mao H, et al. A novel long non-coding RNA FOXCUT and mRNA FOXC1 pair promote progression and predict poor prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(6):2838-49

75. Huang J, Li Y, Lu Z, Che Y, Sun S, Mao S, et al. Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. Cancer Med. 2018. https://doi.org/10.1002/cam4.1524

76. Ke K, Sun Z, Wang Z. Downregulation of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma. Oncol Lett. 2018;16(2):1801-8. https://doi.org/10.3892/ol.2018.8797

77. Wang G, Sun J, Zhao H, Li H. Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit. 2018;24:7689-96. https://doi.org/10.12659/MSM.910867

78. Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y, et al. Long non-coding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. Dis Esophagus. 2017;30(1):1-9. https://doi.org/10.1111.dote.12481

79. Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, et al. Long non-coding RNA HNFIA-ASI regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut. 2014;63(6):881-90. https://doi.org/10.1136/gutjnl-2013-305266

80. Wang G, Zhao W, Gao X, Zhang D, Li Y, Zhang Y, et al. HNFIA-ASI promotes growth and metastasis of esophageal squamous cell carcinoma by sponging miR214 to upregulate the expression of SOX-4. Int J Oncol. 2017;51(2):657-67. https://doi.org/10.3892/ijo.2017.4034

81. Da C, Wu L, Liu Y, Wang R, Li R. Effects of irradiation on radioresistance, HOTAIR and epithelial-mesenchymal transition/cancer stem cell marker expression in esophageal squamous cell carcinoma. Oncol Lett. 2017;13(4):2751-7. https://doi.org/10.3892/ol.2017.5774

82. Li X, Wu Z, Mei Q, Li X, Guo M, Fu X, et al. Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in esophageal squamous cell carcinoma. Br J Cancer. 2013;109(8):2266-78. https://doi.org/10.1038/bjc.2013.548

83. Ren K, Li Y, Lu H, Li Z, Li Z, Wu K, et al. Long Noncoding RNA HOTAIR Controls Cell Cycle by Functioning as a Competing Endogenous RNA in Esophageal Squamous Cell Carcinoma. Transl Oncol. 2016;9(6):489-97. https://doi.org/10.1016/j.tranon.2016.09.005

84. Wang W, He X, Zheng Z, Ma X, Hu X, Wu D, et al. Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. Mol Cancer. 2017;16(1):75. https://doi.org/10.1186/s12943-017-0643-6

85. Xu F, Zhang J. Long non-coding RNA HOTAIR functions as miRNA sponge to promote the epithelial to mesenchymal transition in esophageal cancer. Biomed Pharmacother. 2017;90:888-96. https://doi.org/10.1016/j.biopha.2017.03.103

86. Chen JI, Lin ZX, Qin YS, She YQ, Chen Y, Chen C, et al. Over-expression of long noncoding RNA LINC00419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation. Ther Adv Med Oncol. 2019;11:1758835919838958. https://doi.org/10.1177/1758835919838958

87. Wang PL, Liu B, Xia Y, Pan CF, Ma T, Chen YJ. Long non-coding RNA-Low Expression in Tumor inhibits the invasion and metastasis of esophageal squamous cell carcinoma by regulating p53 expression. Mol Med Rep. 2016;13(4):3074-82. https://doi.org/10.3892/mmr.2016.4913

88. Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, et al. A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma. Sci Rep. 2018;8(1):8823. https://doi.org/10.1038/s41598-018-27307-2

89. Liang Y, Wu Y, Chen X, Zhang S, Wang K, Guan X, et al. A novel long noncoding RNA linc00460 up-regulated by CBP/P300 promotes carcinogenesis in esophageal squamous cell carcinoma. Biosci Rep. 2017;37(5). https://doi.org/10.1042/BSR20171019

90. Ghaffar M, Khodahemmati S, Li J, Shahzad M, Wang M, Wang Y, et al. Long Non-coding RNA LINC01234 Regulates Proliferation, Invasion and Apoptosis in Esophageal Cancer Cells. J Cancer. 2018;9(22):4242-9. https://doi.org/10.7150/jca.26095

91. Wang L, Meng D, Wang Y, Hu J. Long non-coding RNA LINC01296 promotes esophageal squamous cell carcinoma cell proliferation and invasion by epigenetic suppression of KLF2. Am J Cancer Res. 2018;8(10):2020-9

92. Xie JJ, Jiang YY, Jiang Y, Li CQ, Lim MC, An O, et al. Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma. Gastroenterology. 2018;154(8):2137-51 e1. https://doi.org/10.1053/j.gastro.2018.02.018

93. Li CQ, Huang GW, Wu ZY, Xu YJ, Li XC, Xue YJ, et al. Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma. Oncogenesis. 2017;6(2):e297. https://doi.org/10.1038/oncsis.2017.1

94. Cao X, Zhao R, Chen Q, Zhao Y, Zhang B, Zhang Y, et al. MALAT1 might be a predictive maker of poor prognosis in patients who underwent radical resection of middle thoracic esophageal squamous cell carcinoma. Cancer Biomark. 2015;15(6):717-23. https://doi.org/10.3233/CBM-150513

95. Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem. 2015;290(7):3925-35. https://doi.org/10.1074/jbc.M114.596866

96. Chen X, Kong J, Ma Z, Gao S, Feng X. Up regulation of the long non-coding RNA NEAT1 promotes esophageal squamous cell carcinoma progression and correlates with poor prognosis. Am J Cancer Res. 2015;5(9):2808-15

97. Li Y, Chen D, Gao X, Li X, Shi G. LncRNA NEAT1 Regulates Cell Viability and Invasion in Esophageal Squamous Cell Carcinoma through the miR-129/CTBP2 Axis. DisMarkers. 2017;2017:2017:2017. https://doi.org/10.1155/2017/2017:2017

98. Li Y, Li J, Luo M, Zhou C, Shi X, Yang W, et al. Novel long noncoding RNA NMR promotes tumor progression via NSUN2
and BPTF in esophageal squamous cell carcinoma. Cancer Lett. 2018;430:57-66. https://doi.org/10.1016/j.canlet.2018.05.013

99. Tan B, Wang J, Song Q, Wang N, Jia Y, Wang C, et al. Prognostic value of PAX9 in patients with esophageal squamous cell carcinoma and its prediction value to radiation sensitivity. Mol Med Rep. 2017;16(1):806-16. https://doi.org/10.3892/mmr.2017.6626

100. Shi WH, Wu QQ, Li SQ, Yang TX, Liu ZH, Tong YS, et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma. Tumour Biol. 2015;36(4):2501-7. https://doi.org/10.1007/s13277-014-2863-3

101. Meng B, Xing Y, Li H, Gao F, Liu YC. Knockdown of Long Noncoding RNA POU5F1B Promotes Radiosensitivity in Esophageal Carcinoma. Med Sci Monit. 2019;25:1214-9. https://doi.org/10.12659/MSM.913066

102. Zhang Y, Jin X, Wang Z, Zhang X, Liu S, Liu G. Downregulation of SNHG1 suppresses cell proliferation and invasion by regulating Notch signaling pathway in esophageal squamous cell cancer. Cancer Biomark. 2017;21(1):89-96. https://doi.org/10.3233/CBM-170286

103. Zhang Y, Miao Y, Shang M, Liu M, Liu R, Pan E, et al. LincRNA-p21 leads to G1 arrest by p53 pathway in esophageal squamous cell carcinoma. Cancer Manag Res. 2019;11:6201-14. https://doi.org/10.2147/CMAR.S197557

104. Wu Y, Chen X, Liang Y, Li J, Zhang K, Dai L, et al. Overexpression of long non-coding RNA SOX2OT promotes esophageal squamous cell carcinoma growth. Cancer Cell Int. 2018;18:76. https://doi.org/10.1186/s12935-018-0570-7

105. Xie HW, Wu QQ, Zhu B, Chen PJ, Ji L, Li SQ, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol. 2014;35(8):7743-54. https://doi.org/10.1007/s13277-014-2013-y

106. Liu F, Gong R, He B, Chen F, Hu Z. TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis. BMC Cancer. 2018;18(1):894. https://doi.org/10.1186/s12885-018-4804-9

107. Chang ZW, Jia YX, Zhang WJ, Song LJ, Gao M, Li MJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res. 2018;37(1):56. https://doi.org/10.1186/s13046-018-0724-4

108. Kang K, Huang YH, Li HP, Guo SM. Expression of UCA1 and MALAT1 long-chain non-coding RNAs in esophageal squamous cell carcinoma tissues is predictive of patient prognosis. Arch Med Sci. 2018;14(4):752-9. https://doi.org/10.5114/aoms.2018.73713

109. Li JY, Ma X, Zhang CB. Overexpression of long non-coding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(11):7938-44

110. Wang YL, Bai Y, Yao WJ, Guo L, Wang ZM. Expression of long non-coding RNA ZEB1-AS1 in esophageal squamous cell carcinoma and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015;8(9):11871-6

How to cite this article: Xue W, Zheng Y, Shen Z, et al. Involvement of long non-coding RNAs in the progression of esophageal cancer. Cancer Commun. 2021;41:371–388. https://doi.org/10.1002/cac2.12146